Cannabinoïdes
Les cannabinoïdes sont une classe de composés chimiques divers dérivés des acides gras ou des polykétides, qui agissent sur les récepteurs cannabinoïdes des cellules, modifiant ainsi la libération de neurotransmetteurs dans le cerveau. Principalement présents dans les plantes de cannabis, des cannabinoïdes comme le THC et le CBD sont largement étudiés pour leurs effets thérapeutiques, notamment le soulagement de la douleur, leurs propriétés anti-inflammatoires, et leur utilisation potentielle dans les maladies neurodégénératives. Chez CymitQuimica, vous trouverez une grande variété de cannabinoïdes pour la recherche en pharmacologie, neurobiologie, et chimie médicale.
299 produits trouvés pour "Cannabinoïdes"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
GP 1a
CAS :<p>GP 1a: potent CB2 receptor agonist (EC50=7.1), 30x CB2 over CB1 preference, boosts P-ERK1/2, aids skin healing, anti-inflammatory.</p>Formule :C23H22Cl2N4ODegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :441.35GW 833972A
CAS :<p>GW 833972A: selective CB2 agonist; reduces neural depolarization and citric acid cough in animals.</p>Formule :C18H14Cl2F3N5ODegré de pureté :99.93%Couleur et forme :SoildMasse moléculaire :444.24Cannabichromevarin
CAS :Produit contrôlé<p>Cannabichromevarin is a phytocannabinoid naturally found in very low levels compared to other cannabinoids from which it differs in having a propyl chain in place of a pentyl chain1. Based on its structure, it is believed to act as a potent anandamine inhibitor similarly to cannabichromene, however, the majority of its pharmacological and toxicological properties are currently unknown. In vitro assays have shown cannabichromevarin protect against oxidative stress in vitro in macrophages2. It was recently shown to be effective for treatment-resistant epilepsy in a patented combination with cannabidiol in a recent open-ended clinical trial3.</p>Formule :C19H26O2Degré de pureté :Min. 95%Masse moléculaire :286.41 g/molTaranabant
CAS :<p>Taranabant: potent CB1 receptor inverse agonist; inhibits agonists with 0.13 nM Ki in vitro.</p>Formule :C27H25ClF3N3O2Degré de pureté :99.06% - 99.06%Couleur et forme :SolidMasse moléculaire :515.96MDA77
CAS :<p>MDA77 is a CB2 agonist with an EC50 value of 5.82 nM and exhibits no activity towards CB1.</p>Formule :C21H23N3O3Couleur et forme :SolidMasse moléculaire :365.43FDU-PB-22
CAS :<p>FDU-PB-22, a novel synthetic cannabinoid, undergoes rapid metabolism in human liver microsomes (HLM) with a half-life of 12.4 minutes.</p>Formule :C26H18FNO2Couleur et forme :SolidMasse moléculaire :395.431'-Naphthoyl-2-methylindole
CAS :<p>1'-Naphthoyl-2-methylindole (Compound 88) acts as a cannabinoid mimic and an inhibitor of Win 55212-2, displaying a 34% inhibition of [3H]Win 55212-2 binding to cannabinoid receptors at a concentration of 3 μM.</p>Formule :C20H15NOCouleur et forme :SolidMasse moléculaire :285.34MDA7
CAS :<p>MDA7 is a selective agonist of the cannabinoid receptor 2 (CB2), demonstrating an EC50 of 128 nM in human CB2 receptors and 67.4 nM in rat CB2 receptors. The compound exhibits good affinity for CB2 receptors, with Ki values of 422 nM for humans and 238 nM for rats. In rat models, MDA7 shows analgesic activity.</p>Formule :C22H25NO2Couleur et forme :SolidMasse moléculaire :335.439CBR Agonist-2
<p>CBR Agonist-2: CB1 receptor agonist, EC50 - 960 nM, Ki - 970 nM, useful for hCB1R-related disease research.</p>Formule :C27H27FN4OCouleur et forme :SolidMasse moléculaire :442.53CBR Agonist-1
<p>CBR Agonist-1 targets CB1R and CB2R with Ki of 0.18 μM and 1.22 μM, useful for studying cannabinoid-related diseases.</p>Formule :C27H27FN4OCouleur et forme :SolidMasse moléculaire :442.53AM8936
<p>AM8936: potent CB1 agonist, EC50 rCB1=8.6nM/hCB1=1.4nM, Ki rat CB1=0.55nM; potential for CNS, metabolic, pain, glaucoma research.</p>Formule :C25H33NO3Couleur et forme :SolidMasse moléculaire :395.53GAT564
<p>GAT564, an allosteric CB1R modulator, shows EC50s of 87 nM (cAMP) & 320 nM (β-arrestin2) and lowers IOP effectively in glaucoma mice.</p>Formule :C20H16N2O2SCouleur et forme :SolidMasse moléculaire :348.42Bzo-poxizid
CAS :<p>Bzo-poxizid is a synthetic cannabinoid and a psychoactive substance.</p>Formule :C20H21N3O2Couleur et forme :SolidMasse moléculaire :335.40HU 433
CAS :<p>HU 433, a synthetic cannabinoid, acts as a CB2 receptor agonist and is an enantiomer of HU 308. It provides anti-inflammatory and neuroprotective effects by binding to the CB2 receptor, primarily found on immune cells, thereby modulating immune responses and inflammation. Additionally, HU 433 influences microglial signaling pathways, particularly LPS and IFNγ-mediated routes, affecting the phosphorylation of MAPKs, including ERK1/2, JNK, p38, and Akt. This compound is valuable in researching neuroinflammation and retinal diseases.</p>Formule :C27H42O3Couleur et forme :SolidMasse moléculaire :414.62CB1/2 receptor-1
CAS :<p>CB1/2 receptor-1 (compound 5.3) serves as an agonist for CB1/2 receptors and is utilized in angiogenesis research.</p>Formule :C33H48O2Couleur et forme :SolidMasse moléculaire :476.73TM38837
CAS :<p>CB1 antagonist 4 is an inverse agonist of cannabinoid receptor 1 (CB1) with an IC50 of 0.4 nM. It can reduce body weight, improve plasma inflammatory markers, and enhance glucose homeostasis [1].</p>Formule :C27H20Cl2F3N7OCouleur et forme :SolidMasse moléculaire :586.40AB-FUBINACA 3-fluorobenzyl isomer
CAS :<p>AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid and an indazole derivative, exhibiting high affinity for central CB1 receptors (Ki= 0.9 nM) and possessing anticonvulsant activity.</p>Formule :C20H21FN4O2Couleur et forme :SolidMasse moléculaire :368.41CB2 receptor antagonist 1
CAS :<p>Compound 29 is a potent, CB2-selective antagonist/reverse agonist. Derivatives 23 & 24 offer antinociception; 24 activates cannabinoid/TRPV1 receptors.</p>Formule :C28H47NO3Couleur et forme :SolidMasse moléculaire :445.68BNS808
CAS :<p>BNS808 is an orally active, selective CB1R antagonist with an IC50 of 0.8 nM, demonstrating significant selectivity for CB2R and minimal brain penetration. It is being studied for the treatment of obesity and related metabolic complications, such as metabolic dysfunction-associated steatotic liver disease (MASLD). BNS808 reduces drug exposure to the central nervous system, enhancing safety, and minimizes drug interactions through high plasma protein binding.</p>Formule :C25H20Cl3N3O3SCouleur et forme :SolidMasse moléculaire :548.869MDMB-FUBICA
CAS :<p>MDMB-FUBICA is a potent agonist of the cannabinoid receptors and exhibits psychoactive properties. It can be utilized in e-cigarettes.</p>Formule :C23H25FN2O3Couleur et forme :SolidMasse moléculaire :396.455
